Abstract Library

#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma

Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.

Conference:

Presenting Author: Zhang L

Authors: Falkman L, Zhang L, Welin S, Crona J,

Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,

#3810 A patient with BRAF V600E mutated colon-NEC showing response to BRAF- and MEK inhibitors

Introduction: Preclinical studies have reported that the BRAF V600E mutation is a druggable target in colorectal neuroendocrine carcinomas (NECs). At least one case report has presented clinical success in the treatment of colorectal NEC using a BRAF inhibitor.

Conference:

Presenting Author:

Authors: Falkman L, Sundin A, Crona J, Wallin G, Welin S,

Keywords: neuroendocrine carcinoma, BRAF V600E, dabrafenib, trametinib, colorectal nec,

#3129 Colorectal NECs and MANECs: A monocenter pilot retrospective analysis

Introduction: Poorly-differentiated neuroendocrine carcinomas (NECs) and mixed adeno-neuroendocrine carcinomas (MANECs) are rare and aggressive neoplasms whose tumorigenesis pathways are still unknown and clinical management not universally shared.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Laffi A, Spada F, Ranghiero A, Pisa E, Barberis M,

Keywords: mutational, genetic, neuroendocrine, NEC, MANEC, carcinogenesis, colorectal,

#2123 Large Cell Neuroendocrine Carcinoma (LCNEC) Associated with a Dysplastic Sessile Serrated Lesion (SSL) and Deficient Mismatch Repair (MMR) Protein: A Case Report.

Introduction: Colorectal poorly differentiated neuroendocrine carcinomas (NECs) are rare, but extremely aggressive. The mechanisms of their carcinogenesis and aggressiveness are still largely unknown. Recently Nobuyoshi Takizawa showed that the molecular features of colorectal NECs are similar to those of adenocarcinoma and not to those of NETs and they were more evident in small cell NECs than in large cell NECs. This is supported by combined cases with conventional adenoma/adenocarcinoma and NECs. Stelow et al showed that DNA mismatch repair proteins were intact in 14/15 colorectal small cell NECs. Two cases of LCNECs arising from SSL have been reported so far in the literature.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Luong T

Authors: Luong T, Nisa Z,

Keywords: Large cell neuroendocrine carcinoma, sessile serrated lesion, microsatellite instability, MMR protein, BRAF mutation,